Author: 59admin_north

CuraCell's head of clinical operations, Torbjörn Ström, spoke with Clinical Leader Executive Editor Abby Proch about the company’s efforts to reshape the future of T‑cell therapy for cold solid tumors. The interview explores how CuraCell’s CytoPLY platform rejuvenates a patient’s own tumor‑infiltrating lymphocytes (TILs), improving their expansion, potency, and cytokine production without genetic modification — a strategy designed to overcome the limitations of conventional cell therapies.

Ström highlights encouraging early activity across prostate cancer, glioblastoma, pancreatic cancer, and renal cell carcinoma, supporting CuraCell’s belief that a “polyclonal, unselected TIL approach may have broader applicability than many targeted therapies.” These insights have shaped CC‑38, the company’s first clinical candidate now in Phase I/IIa trials, which uses gentler preconditioning, multi‑dose administration, and a streamlined manufacturing process to reduce treatment burden and expand access for patients with cold solid tumors.

Read the full conversation here.

In pharmaphorum, reporter Nicole Raleigh spotlights Gothenburg’s rise as one of Europe’s most dynamic life sciences hubs, describing how the region now accounts for more than a third of Sweden’s total business R&D expenditure. Her piece highlights the country’s broader momentum — from major acquisitions and government sustainability investments to cutting‑edge academic research and biotech breakthroughs — illustrating how Sweden’s collaborative model between industry, academia and the public sector continues to fuel innovation.

Raleigh’s visit to GoCo Health Innovation City showcases this ecosystem in action, including Thermo Fisher Scientific’s newly opened bioanalytical laboratory and its partnership with AstraZeneca’s BioVentureHub. Leaders from both organisations outline how co‑location, shared capabilities and Sweden’s deep talent pool create ideal conditions for next‑generation drug development, digital health integration and cross‑sector innovation. The article frames Gothenburg as a uniquely fertile environment where global companies, start‑ups and researchers converge — and where Sweden’s culture of openness and resource‑sharing is driving life sciences growth well beyond its size.

Read the full article here.

In ONdrugDelivery, Nanexa’s Anders Johansson, Polla Rouf and Oliver Hedge outline how the company’s PharmaShell ALD nanocoating technology is enabling once‑monthly — and potentially once‑quarterly — injectable therapies. The authors explain how ultra‑thin, inorganic ALD coatings applied to drug microparticles create highly controlled depot formulations that dissolve at a tuned rate, delivering steady drug release over weeks to months. By avoiding polymer‑based systems and their unpredictable burst‑and‑tail behaviour, PharmaShell achieves flatter pharmacokinetic profiles, reduced peak‑related side effects and significantly lower dosing frequency.

The article highlights Nanexa’s progress with long‑acting GLP‑1 therapies, including a once‑monthly semaglutide depot supported by preclinical data and earlier clinical proof‑of‑concept from a PharmaShell‑coated liraglutide study. Recent formulation advances have produced near‑linear 30‑day release, improved tolerability and a ready‑to‑use suspension compatible with fine‑gauge needles and autoinjectors. With scale‑up plans underway and device integration progressing, the authors position PharmaShell as a next‑generation delivery platform capable of transforming chronic disease management through smarter, ultra‑long‑acting injectables.

Read the full article here. 

Bree Foster, assistant editor at Drug Discovery News, sat down with Daniel Tillett, the CEO of Racura Oncology, to discuss G-quadruplexes, or G4 structures that are pivotal to the Australian biotech's approach to cancer.

“These G-quadruplex structures are found throughout the genome, but they’re particularly enriched in promoter regions of important genes, where they act as regulatory elements,” Tillett explained.

To read how Racura is using G4 structures in its approach to AML and lung caner, read the full article here.

In a recent column for Clinical Leader, Dicot Pharma CEO Elin Trampe discussed how clinical milestones, financing strategy, shareholder value, and partnering considerations must be tightly integrated in early development through late-stage planning.

She also outlined how maintaining scientific rigour while building long-term commercial value shapes trial design, investor communication, and licensing timing in a competitive biotech landscape.

The full article can be accessed here.

Nanexa’s Senior Scientist Anders Johansson outlines in BioXconomy how the next era of GLP‑1 therapies will be defined not by new molecules, but by smarter delivery. While GLP‑1s have already evolved from twice‑daily injections to once‑weekly dosing, the field is now pushing toward monthly — and even quarterly — regimens to reduce patient burden and improve long‑term adherence. Johansson explains that many ultra‑long‑acting candidates rely on new chemical entities with extended half‑lives, but these approaches come with significant safety, manufacturing and tolerability challenges.

The article highlights an alternative path: using advanced depot technologies to transform existing GLP‑1 drugs into long‑acting formulations. Nanexa’s PharmaShell platform encapsulates GLP‑1 analogues in a nanometer‑thin inorganic coating that prevents burst release and enables controlled dissolution for up to three months. By focusing on delivery rather than redesigning the drug itself, Johansson argues that developers can achieve extended dosing intervals more efficiently — potentially reshaping obesity and diabetes care with fewer injections and better patient experience.

Read the full article here. 

The Pharma Navigator’s interview with Nanexa CEO David Westberg at BIO 2026 explores how the company is engineering long‑acting injectables with unprecedented precision. Westberg explains that moving from daily or weekly dosing to monthly or quarterly regimens hinges on three factors: drug potency, tight control of the release profile, and injectable volumes that remain clinically practical. He highlights the importance of achieving a low peak‑to‑trough ratio to maintain stable therapeutic levels and reduce side effects — an area where Nanexa’s ALD‑based PharmaShell technology has shown strong validation.

The piece spotlights Nanexa’s recent work with semaglutide, where the company achieved peak‑to‑trough ratios below 1.5 for both once‑monthly and once‑quarterly formulations, outperforming commercial weekly products. Westberg details how Nanexa’s gas‑phase, dry ALD coating protects fragile biologics inside the depot, ensuring that molecules released even on day 75 or 90 remain fully intact. The interview positions PharmaShell as a next‑generation solution for long‑acting biologics, offering controlled release, molecular stability and a viable path to extended‑interval dosing.

Watch the video here. 

BioPharma analyst Tierney Baum wrote a detailed profile for BioCentury on NanoPhoria in June. 

"Using a two-level inhalable particle design, NanoPhoria is exploiting the unique connection between the lungs and heart to deliver peptides and nucleic acids to cardiomyocytes, whose inaccessibility has historically limited the use of biologics in cardiovascular diseases," she wrote.

NanoPhoria, who raised the largest Italian Series A round of €83.5m in October 2025, has designed its “Nano-in-Micro” platform to deliver concentrated doses of therapy straight from the lung to the heart, before systemic dilution in the larger circulation. 

The full article can be accessed here.

Dr Rosanne Dunn, Co-Founder and Chief Scientific Officer at HaemaLogiX, authored an article for Drug Discovery World that explored how the discovery of a new class of tumour‑specific antigens is transforming how we treat plasma cell dyscrasias.

"Proteasome inhibitors, immunomodulatory drugs, anti‑CD38 antibodies, and, more recently BCMA‑directed CAR‑T cells and bispecifics, have each extended survival and transformed expectations. But the malignant plasma cell clone adapts, escapes, and ultimately progresses through every line of therapy. The central limitation is not the ingenuity of modalities but the biology of the targets themselves" she said.

Read the full article here. 

In June, Cereno Scientific CMO and Head of R&D Rahul Agrawal spoke with Clinical Leader Executive Editor Abby Proch about the scientific and strategic rationale behind extending the company’s Phase IIb study duration. He also shares how patient input, regulatory guidance, and earlier-phase data shaped a design intended to generate more meaningful and durable insights in a complex, heterogeneous disease.

Read the full article here.